American Century Companies
TPTX

American Century Companies’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

American Century Companies’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-547,354
Closed -$26.1M – 2379
2021
Q4 		$26.1M Sell
547,354
-16
-0% -$715 0.02% 631
2021
Q3 		$36.4M Buy
547,370
+70,237
+15% +$5M 0.02% 533
2021
Q2 		$37.2M Buy
477,133
+114,327
+32% +$8.45M 0.03% 527
2021
Q1 		$34.3M Sell
362,806
-34,193
-9% -$4.07M 0.03% 515
2020
Q4 		$48.4M Sell
396,999
-44,676
-10% -$4.89M 0.04% 398
2020
Q3 		$38.6M Sell
441,675
-56,029
-11% -$3.9M 0.03% 401
2020
Q2 		$32.1M Buy
497,704
+46,404
+10% +$2.68M 0.03% 418
2020
Q1 		$20.2M Buy
451,300
+70,640
+19% +$3.75M 0.02% 449
2019
Q4 		$23.7M Buy
380,660
+67,079
+21% +$3.19M 0.02% 472
2019
Q3 		$11.8M Buy
+313,581
New +$13.7M 0.01% 585

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

American Century Companies's TPTX Position: Q1 2022 in Review

American Century Companies sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 547,354 shares — an estimated $26.1M sold.

American Century Companies first reported a position in TPTX in Q3 2019 and held it in 10 quarters. The position peaked at $48.4M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • American Century Companies reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • American Century Companies sold 547,354 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $26.1M.
  • American Century Companies first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
  • American Century Companies's Turning Point Therapeutics, Inc. Common Stock position peaked at $48.4M in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on American Century Companies's 13F filing for Q1 2022, filed 11 May 2022.